Neratinib Medicare Price 2023
Neratinib (Neratinib)Can be used as monotherapy for extended adjuvant treatment of adults receiving adjuvant trastuzumab treatmentHER2-positive early breast cancer. Subgroup analyzes demonstrated a greater impact on aggressive disease-free survival in patients with hormone receptor-positive disease, those who received sequential adjuvant trastuzumab, and those who completed adjuvant trastuzumab within 1 year of randomization. The recommended dose is 240mg, taken once a day with food, for one year.
Neratinib when used in combination with capecitabine is indicated for the treatment of patients with advanced or metastatic HER2-positive breast cancer who have received ≥2 prior anti-HER2 regimens in the setting of metastasis. In clinical practice guidelines, neratinib plus capecitabine is recommended as one of several potential third-line treatment options for patients with advanced HER2-positive breast cancer who have progressed during or after 2 previous anti-HER2 regimens. The recommended dose is 240 mg orally once daily with food on days 1-21 of a 21-day cycle, plus capecitabine (750 mg/m2 orally twice daily) on days 1-14 of a 21-day cycle until disease progression or unacceptable toxicity.
In 2023, the original drug of neratinib has entered the scope of Class B medical insurance after being launched in China, but it is only reimbursable for patients who meet the indications. The price of each box of 40mg*180 tablets may be more than 7,000 yuan. The reimbursement ratio is different in different regions. The price after reimbursement may be different. For details, please consult the local medical insurance bureau or hospital. Generic drugs of neratinib are also sold overseas. The drug ingredients are basically the same as those of the original drug. The price of 40mg*180 tablets produced by Bangladesh pharmaceutical factory may be around 4,000 yuan per box (the price may fluctuate due to the exchange rate). For more information about overseas drugs and specific prices, please consult Yaode Medical Consultant.
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)